Triple
T22880684
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Tommy Thompson |
E567457
|
entity |
| Predicate | boardMemberOf |
P10
|
FINISHED |
| Object | United Therapeutics |
—
|
NE NERFINISHED |
How this triple was built (3 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: United Therapeutics | Statement: [Tommy Thompson, boardMemberOf, United Therapeutics]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: United Therapeutics Context triple: [Tommy Thompson, boardMemberOf, United Therapeutics]
-
A.
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals is a leading American biotechnology company known for developing innovative antibody-based therapies for serious diseases, including eye disorders, cancer, and inflammatory conditions.
-
B.
Alexion Pharmaceuticals
Alexion Pharmaceuticals is a biopharmaceutical company specializing in the development of therapies for rare and severe diseases, particularly in the field of complement biology.
-
C.
Novartis Gene Therapies
Novartis Gene Therapies is a biotechnology company within Novartis focused on developing and commercializing gene therapy treatments for rare and life-threatening genetic diseases.
-
D.
Guardant Health
Guardant Health is a precision oncology company specializing in blood-based liquid biopsy tests to detect, monitor, and guide treatment of cancer.
-
E.
Mapp Biopharmaceutical
Mapp Biopharmaceutical is a U.S.-based biotechnology company best known for developing antibody-based therapies for infectious diseases, including experimental treatments for Ebola.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: United Therapeutics Target entity description: United Therapeutics is a biotechnology company focused on developing and commercializing therapies for pulmonary arterial hypertension and other serious cardiopulmonary conditions.
-
A.
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals is a leading American biotechnology company known for developing innovative antibody-based therapies for serious diseases, including eye disorders, cancer, and inflammatory conditions.
-
B.
Alexion Pharmaceuticals
Alexion Pharmaceuticals is a biopharmaceutical company specializing in the development of therapies for rare and severe diseases, particularly in the field of complement biology.
-
C.
Novartis Gene Therapies
Novartis Gene Therapies is a biotechnology company within Novartis focused on developing and commercializing gene therapy treatments for rare and life-threatening genetic diseases.
-
D.
Guardant Health
Guardant Health is a precision oncology company specializing in blood-based liquid biopsy tests to detect, monitor, and guide treatment of cancer.
-
E.
Mapp Biopharmaceutical
Mapp Biopharmaceutical is a U.S.-based biotechnology company best known for developing antibody-based therapies for infectious diseases, including experimental treatments for Ebola.
- F. None of above. chosen
Provenance (2 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69e2458a92ec81908fc1cd5f6407d2ab |
completed | April 17, 2026, 2:36 p.m. |
| NER | Named-entity recognition | batch_69f17f5c1ed88190aeac131c5aff6102 |
completed | April 29, 2026, 3:47 a.m. |
Created at: April 17, 2026, 3:39 p.m.